High Voltage Engineering Corporation
| Company type | Private (formerly public) |
|---|---|
| Industry | Particle accelerators, Nuclear physics equipment |
| Founded | 1946 |
| Founder | John G. Trump, Robert Van de Graaff, Denis M. Robinson |
| Fate | Filed for bankruptcy protection in 2005 |
| Headquarters | Cambridge, Massachusetts (initially), later Burlington, Massachusetts , United States |
| Products | Particle accelerators, Van de Graaff generators, Tandem accelerators, Radiation technology products |
Number of employees | 140 (circa early 1950s) |
| Parent | None |
High Voltage Engineering Corporation (HVEC) was a pioneering American firm specializing in particle accelerator manufacturing and stood among the earliest companies supported by venture capital. HVEC’s equipment played a leading role in nuclear physics research and facilitated three significant commercial applications of particle accelerators: oncology treatments, industrial sterilization processes, and semiconductor fabrication.
The company emerged from high-voltage research conducted at the Massachusetts Institute of Technology (MIT) by Robert Van de Graaff and John G. Trump. In 1946, Trump established HVEC with the objective of producing a portable Van de Graaff generator to make cancer radiotherapy more accessible and cost-effective. He enlisted Van de Graaff and Denis M. Robinson as co-founders, initiating manufacturing operations in a garage located in Cambridge, Massachusetts.
As government funding for physics research expanded, HVEC transitioned from focusing on medical equipment to manufacturing large-scale, truck-sized research particle accelerators. Its tandem accelerators became the preferred choice for nuclear physics investigations during the 1960s and 1970s, with numerous universities and government laboratories acquiring these systems. At least 32 of HVEC’s research accelerators continue to operate today, including four housed at U.S. national laboratories.
Following shifts in funding in 1968, HVEC halted production of new research accelerators and restructured into a diversified conglomerate. Leadership after 1970 concentrated on products utilizing radiation technology, divested its accelerator manufacturing division, and gradually sold off its subsidiaries. The company was taken private in 1988 and ultimately filed for bankruptcy protection in 2005.
HVEC and its affiliated companies made seminal contributions to the commercialization of particle accelerator technologies. Their original accelerator models spearheaded the early market for artificial radiotherapy, enabling hospitals and patients to access affordable treatment options. HVEC was instrumental in developing commercial ion implantation techniques essential to semiconductor production, and its machines were among the first employed for commercial radiosterilization of medical supplies. Many of their innovations continue to be extensively applied in ion implantation and heat-shrink material processes.
As one of the initial trio of companies funded by the American Research and Development Corporation (ARD)—the first modern venture capital firm—HVEC represented ARD’s largest holding at its 1963 initial public offering. This success helped sustain ARD’s formative growth phase and validated the potential of venture capital investments.
Founding and early development
The particle accelerators produced by High Voltage Engineering Corporation trace their origins to an electrostatic generator invented by MIT physicist Robert J. Van de Graaff. Aiming to achieve atomic disintegration, Van de Graaff developed an electrostatic acceleration technique capable of propelling charged particles at very high voltages. During the early 1930s, he secured patents on several technologies that formed the core intellectual property for the company. These patents, along with subsequent ones from John Trump, were assigned by MIT to the Research Corporation for licensing purposes.
John G. Trump, a protégé of Van de Graaff at MIT, refined these generators into smaller-scale versions intended for commercial deployment with a focus on cancer therapy applications. At that period, radiation treatment depended heavily on expensive radium sources that often caused damage to healthy tissues. Trump recognized that Van de Graaff’s controllable high-energy generators could offer safer and more economical therapeutic options. He further improved early designs by creating "supervoltage" (1-megavolt) x-ray generators suitable for hospital use and secured patents covering compact units. During World War II, Van de Graaff manufactured compact generators utilized by the Navy for radiographic inspection tasks.
Following the war’s conclusion, Trump received orders from hospitals in Britain and resolved to establish a company to fulfill this demand. He brought Van de Graaff on board as co-founder and chief scientific advisor; however, both preferred to maintain their academic roles at MIT. Consequently, British physicist Denis M. Robinson joined as a third co-founder and assumed the position of president. Robinson had previously served as the British liaison officer to MIT’s Radiation Laboratory during collaborative U.S.–U.K. radar development efforts.
In 1946, Trump approached MIT President Karl Compton—founder of American Research and Development Corporation (ARD), an early venture capital firm supporting technology startups—for backing. Compton introduced HVEC’s founders to ARD president Georges Doriot. Although Doriot was skeptical about the commercial viability of cancer treatment machines given competition from General Electric and Allis Chalmers, he appreciated HVEC’s technical expertise along with Compton’s endorsement emphasizing societal benefits. Out of more than 400 applicants, ARD selected HVEC as one of its initial three investments, providing $200,000 in seed funding in exchange for half ownership. The Lessing J. Rosenwald family contributed an additional $50,000 investment. Compton arranged exclusive licensing agreements granting HVEC rights to MIT’s Van de Graaff and Trump patents; both Compton and Doriot joined HVEC’s board of directors.
Supervoltage cancer treatment
Originating from a modest auto repair shop near Harvard Square, HVEC developed Trump's gas-insulated Van de Graaff generators tailored for hospitals and industrial clients. In 1947, British medical institutions placed the initial orders for HVEC’s compact 2-megavolt units, positioning the company among the pioneers in commercializing artificial radiation devices for oncology applications.
Within a span of three years, HVEC had delivered 17 particle accelerators, expanded its workforce to 140 employees, and achieved $2 million in sales (adjusted value in ), surpassing rivals in both product quality and pricing. Nevertheless, the company faced significant financial strains and technical challenges early on, which nearly depleted its capital on several occasions.
By the mid-1950s, emerging technologies such as General Electric’s cobalt-60 machines, known for their simpler operation and reduced maintenance requirements, became dominant choices for hospitals. Although HVEC continued serving the medical sector until 1969, it gradually redirected its efforts toward redesigning generators for research laboratories and industrial applications.
Shift toward scientific instrumentation
While initially focusing on customers in cancer therapy and industrial radiography, HVEC’s equipment found growing acceptance in fundamental scientific research. Its proximity to MIT facilitated close partnerships with physicists, enabling customization of accelerator designs to meet advanced nuclear experimentation needs.
In 1949, Brookhaven National Laboratory contracted HVEC to construct a 4 MeV Van de Graaff injector for its high-energy Cosmotron accelerator. Completed in 1953, the Cosmotron was the first machine to exceed billion-electronvolt energy levels. HVEC’s standard 2 MV accelerators were also utilized by nuclear research entities such as the Naval Research Laboratory and various European universities. Although other accelerators could achieve higher voltages, Van de Graaff generators provided consistent electrostatic power and flexible beam control essential for precision experiments.
In 1951, HVEC adopted an MIT accelerator design by Trump as a model for mass-producing single-stage "CN" accelerators capable of reaching up to 6.5 megavolts, cementing its reputation for dependable nuclear research equipment. In 1954, Canada’s Chalk River Laboratories commissioned a more advanced tandem accelerator, which led to a successful product line that sustained HVEC’s business for fifteen years.
Outgrowing its Cambridge garage facility, HVEC inaugurated a manufacturing plant on Route 128 in Burlington, Massachusetts in 1957. Concurrently, it established High Voltage Engineering Europa to serve the European common market.
The Sputnik crisis of 1957 broadened commercial prospects for nuclear instrumentation as U.S. government agencies increased funding for university and national laboratory acquisition of research accelerators. HVEC’s dependable production platforms became favored tools in this environment. Over the next fifteen years, the company delivered 55 tandem accelerators priced between $1 million and $3 million each to laboratories across seven countries. By the mid-1970s, nearly 70% of published experimental nuclear physics research relied on data generated by HVEC accelerators.
Entering the 1960s as the foremost particle accelerator manufacturer in the United States, HVEC’s annual revenue grew from $1 million in 1954 to $17 million by 1962. When listed on the New York Stock Exchange in 1963, HVEC accounted for over 40% of ARD's portfolio assets, increasing ARD's initial $0.2 million investment to $13 million.
The Transuranium Initiative
Van de Graaff, who was already serving as chief scientist, became a full-time member of HVEC in 1960 and played a key role in introducing the industrial core transformer. His main focus was the development of the ambitious 20-megavolt Transuranium Accelerator (XTU), designed to synthesize superheavy elements theorized to exist within the so-called "island of stability" beyond uranium. These elements were considered promising candidates for nuclear fuel in space exploration or compact nuclear weaponry, making the synthesis of superheavy ions HVEC’s foremost accelerator research priority.
HVEC committed over $4.6 million toward two XTU prototypes, implementing a "construct first, attract clients later" approach to establish leadership in this cutting-edge technology sector. Nevertheless, during the 1967–68 construction phase, federal support for nuclear physics research sharply declined due to shifting government priorities amid the Vietnam War and Great Society programs. At the same time, breakthroughs in particle physics moved research beyond what Van de Graaff accelerators could achieve. By the time the XTU completed initial testing, funding from the U.S. Atomic Energy Commission was withdrawn, forcing HVEC to suspend the XTU project and shut down its Van de Graaff Research Laboratory located in Burlington.
This setback occurred alongside mounting competitive challenges. Technical difficulties with HVEC’s Emperor tandem accelerators undermined its market standing as competitors reported expensive component failures. In 1969, former HVEC consultant Raymond Herb established National Electrostatics Corporation, whose robust Pelletron charging system became the preferred technology for federally funded accelerator projects. HVEC ultimately sold its final two Emperor units to French national laboratories in 1973.
Diversification and Decline
The financial turmoil of the early 1970s triggered a significant strategic realignment at HVEC. In 1970, losses reached 31 percent of shareholder equity. The company responded by laying off 100 staff members and halting numerous research initiatives, attributing these measures to diminished federal funding. That same year brought leadership changes: Pascal Levesque, who led the profitable subsidiary Electronized Chemicals Corporation, assumed the roles of president and CEO, while former president Denis Robinson transitioned to chairman.
Under Levesque’s guidance, HVEC expanded into industrial uses for its accelerator technology. By 1972, it had evolved into a miniconglomerate comprising over ten subsidiaries manufacturing plastics, power equipment, and radiation processing devices—products derived from particle accelerator applications rather than accelerators themselves. This pivot produced successful offerings such as Electronized Chemicals’ heat-shrink tubing vital for automotive and aerospace wiring harnesses and Ion Physics Corporation’s radiation-based ion implantation process, which eventually became a semiconductor industry standard. Industrial product sales surged to constitute 80 percent of total revenue, up from just 30 percent earlier.
Despite this diversification effort, HVEC faced ongoing profitability challenges amid competition from larger conglomerates. By 1981, it ceased accelerator manufacturing and divested its Burlington facility two years afterward. The company redirected focus toward smaller industrial goods including specialty plastics, wires, industrial instruments, and electrical connectors but gradually divested these operations throughout the 1980s.
In 1988, private equity firm Hyde Park Partners proposed taking HVEC private at approximately twice its market value. Despite opposition from Levesque, shareholders approved the transaction in 1989. Hyde Park replaced management personnel, liquidated remaining real estate holdings, and relocated headquarters to Charlestown, Massachusetts. HVEC filed for bankruptcy protection in 2005. Since 2019, Oak Point Partners has managed the company’s residual corporate assets.
Accelerator products
Between 1946 and 1981, HVEC produced approximately 471 particle accelerators, while its former European branch, High Voltage Engineering Europa, manufactured an additional 93 units from 1958 to 2005. Over a span of 25 years, the company's Van de Graaff accelerator range progressed from compact 2.5-meter medical X-ray generators to large 24.5-meter tandem accelerators designed for nuclear physics investigations. HVEC also pioneered the insulating core transformer, a high-voltage DC generator applied extensively in industrial radiation processing. These technological advancements enabled commercial electron-beam sterilization, polymer radiation crosslinking, and ion implantation processes utilized in semiconductor fabrication.
Medical equipment
HVEC initially concentrated on cancer therapy equipment, illustrating the commercial potential of controlled particle acceleration within medical applications. From 1948 through 1969, the company manufactured compact 2-megavolt electron accelerators intended for hospital radiotherapy units. Measuring roughly eight feet in length, these generators were user-friendly enough for operation by technicians and nursing staff, thus broadening access to radiation treatment beyond leading research institutions. During this period, 35 hospitals across the United States and eight international facilities adopted these systems for oncological treatment.
These generators effectively addressed the drawbacks of traditional radium-based radiotherapy—which was expensive, limited in availability, and prone to uncontrolled radiation exposure—by generating artificial X-rays capable of precise targeting and modulation. This precision allowed clinicians to concentrate radiation doses on tumors while sparing surrounding healthy tissues. Adjustable beam energies corresponded to tumor depths, and fractionated dosing protocols helped mitigate adverse effects.
HVEC also contributed to medical research through equipment used in collaborative programs between the Lahey Clinic and MIT’s Trump laboratory, where rotational radiation delivery techniques from multiple angles became standard practice in cancer therapy. In 1952, HVEC constructed a compact linear accelerator for the University of Chicago’s Argonne Cancer Research Hospital, capable of producing electrons with energies ranging from 10 to 50 MeV. This device played a key role in advancing high-energy radiation therapy research that influenced clinical treatment strategies.
By the mid-1950s, cobalt-60 therapy units produced by General Electric began supplanting electron accelerators due to their simpler operation and lower upkeep costs despite offering less precise energy control. Consequently, HVEC withdrew from the medical device sector in 1969 to concentrate on research and industrial markets where sophisticated beam control was essential.
Industrial radiography
During World War II, Van de Graaff and Trump developed a compact generator deployed by the U.S. Navy for detecting defects in ship hulls and munitions. Building on this innovation, HVEC manufactured 2-MeV industrial X-ray generators designed for non-destructive testing of manufactured components. These robust units were tailored for industrial environments and capable of identifying flaws within thick steel structures.
HVEC subsequently modified these generators to produce electron beams, marketing industrial radiography equipment alongside offering sterilization rental services. In 1957, Ethicon—a subsidiary of Johnson & Johnson—acquired an HVEC linear accelerator to sterilize surgical sutures, marking the first commercial medical product processed by radiation methods. By 1960, Ethicon transitioned to gamma irradiation systems to achieve deeper material penetration.
Sales of electron-beam processing machinery surged following HVEC’s introduction of insulating core transformers (ICTs), which operated within the energy range of 300 keV to 2.5 MeV. ICT technology found applications in crosslinking polyethylene and other polymers. W. R. Grace’s Cryovac division utilized radiation crosslinking techniques to manufacture heat-shrinkable packaging materials for the food industry. Additional sectors adopted ICTs for enhancing wire and cable insulation, rubber vulcanization processes, automotive paint curing, textile modification, and semiconductor production.
As part of its conglomerate expansion strategy, HVEC’s subsidiary Electronized Chemicals Corporation (ECC) developed proprietary products leveraging HVEC equipment. By 1960, ECC’s portfolio included heat-shrink tubing, shrink wrap films, and cross-linked electrical wiring.
In the late 1970s, building on research spearheaded by John Trump, HVEC ventured into environmental applications of electron beam technology. In 1980, it secured a $1 million contract from Miami-Dade County aimed at disinfecting wastewater prior to landfill disposal. Additional projects involved expanding sewage sludge treatment facilities for the Massachusetts Metropolitan District Commission and designing electron beam systems for disinfecting poultry feed.
Research accelerators
HVEC made its entry into the high-energy research accelerator sector in 1949 with the launch of its 4 MV Cosmotron particle injector. By 1951, the company had started manufacturing the single-ended CN series, recognized as the first widely produced research accelerators.
The CN series was inspired by John Trump’s vertical accelerator design at MIT and incorporated features such as resistor grading, field-shaping column hoops, and an insulating gas mixture of nitrogen and carbon dioxide. Operating at voltages up to 6.5 megavolts, HVEC built 26 CN units that were extensively utilized in light-ion nuclear physics studies. Nevertheless, the progression of nuclear physics demanded particle energies exceeding what single-stage Van de Graaff accelerators could deliver.
The tandem principle
A significant advancement originated from Nobel Prize winner Luis Alvarez's 1951 concept of charge reversal. Unlike traditional accelerators that propel positive ions from ground to a high-voltage terminal, the tandem accelerator initially accelerates negative ions toward a positively charged terminal where electron stripping converts them into positive ions. These ions then accelerate back toward ground potential, effectively doubling the particle energy without increasing terminal voltage—for instance, a 5 MV tandem achieves 10 MV kinetic energy.
HVEC commenced tandem accelerator production in 1954, and in 1956 Atomic Energy of Canada Limited placed an order for HVEC’s inaugural tandem unit valued at $0.92 million. The accelerator produced its first beam at HVEC’s Burlington facility in June 1958 and was subsequently installed at Chalk River by February 1959.
Tandem models
Between 1958 and 1973, HVEC developed five progressively advanced tandem models, manufacturing a total of 55 units worldwide that significantly enhanced capabilities in nuclear physics research.
The EN model emerged as HVEC’s flagship production accelerator. Originally designed for a 5 MV terminal voltage but capable of reaching up to 7 MV, it was pioneering as the first large-scale accelerator employing pure sulfur hexafluoride gas for insulation due to its superior dielectric properties. After its initial deployment at Chalk River, HVEC manufactured an additional 29 EN tandems installed across seven different countries.
The commercial viability of the EN model was underpinned by powerful negative ion sources developed at Chalk River and Wisconsin, along with HVEC’s innovation of the inclined-field acceleration tube. This design prevented voltage breakdowns common in earlier models by redirecting secondary particles into electrodes, enabling voltage scaling with tube length and facilitating new experimental work using carbon and oxygen ion beams ranging from 6 to 35 MeV.
Known as the "King" tandem, the FN model featured a larger pressure vessel and extended terminal voltages to a standard 7.5 MV, with "Super FN" variants reaching up to 9 MV through inclined-field tubes. The first FN unit was delivered in 1963 to Los Alamos National Laboratory. Seventeen FN models were sold to various universities and national laboratories including Rutgers, Florida State University, Stanford University, as well as institutions in France and Romania.
The MP model, also called the "Emperor" tandem, represented a significant evolution in design. Commissioned by the U.S. Atomic Energy Commission in late 1962 for operation at 10 MV, it incorporated inclined-field tubes throughout and introduced an "open truss" column structure that balanced mechanical robustness with electrical insulation.
Installed initially at Yale University in 1963, MP units consistently operated within a voltage range of 10 to 11.75 MV; a later installation at Strasbourg achieved voltages up to 18 MV. These enhanced voltages facilitated effective electron stripping of heavy ions such as uranium for nuclear fusion experiments and precise gamma-ray spectroscopy. Between 1965 and 1973, HVEC constructed ten MP units for institutions including the University of Minnesota, Chalk River Laboratories, and the Max Planck Institute Heidelberg. A distinctive three-stage MP tandem built for Brookhaven National Laboratory remains operational as of 2025.
The XTU model, nicknamed the "Holy Roman Emperor," stood as HVEC’s most ambitious design with a rated terminal voltage of 20 MV aimed at superheavy element synthesis. While maintaining the MP’s column length, it expanded the tank diameter to 7.6 meters and eliminated the MP's characteristic "knee" bend. Engineered to accelerate uranium ions close to one billion electron volts—enabling fusion reactions surpassing element 110—the prototypes operated exclusively at HVEC’s Burlington facility before being transferred to Italy’s national laboratories in 1979.
| Model | Type | Nickname | Production years | Tank (l x D) | No. Sold | Rating (MV) | Max. (MV) |
|---|---|---|---|---|---|---|---|
| CN | Single-stage | -- | 1958–1966 | 8.0 x | 26 | 5.5 | -- |
| EN | Tandem | -- | 1958–1973 | 11.0 x 2.4 | 30 | 5 | 7 |
| FN | Tandem | King | 1963–1970 | 13.4 x 3.6 | 17 | 9 | 17 |
| MP | Tandem | Emperor | 1962–1973 | 24.5 x4.5 | 10 | 10 | 18 |
| XTU | Tandem | Holy Roman Emperor | 1967–1969 | 24.5 x7.6 | 2 | 14 | 20 |
Insulated core transformer
In the early 1950s, Van de Graaff recognized the limitations of his belt-driven electrostatic accelerators in delivering sufficient current. He devised a novel voltage generation method that substituted the charging belt with magnetic flux, enabling the conversion of power into high-voltage direct current. This approach entailed designing a segmented magnetic core with insulation capable of withstanding high voltages while permitting the coexistence of electric and magnetic fields. Van de Graaff secured a patent for his single-phase insulating core transformer (ICT) accelerator concept in 1957, which was granted in 1965. Subsequently, engineers at HVEC advanced this technology by creating a commercially practical three-phase variant.
The ICT technology found increasing application within industrial radiation processing. By 1967, it had become established as a principal source of high-voltage DC power for particle acceleration in industrial settings. HVEC provided ICT power supplies for low-voltage electron beam systems alongside its traditional belt-charged accelerators. ICT accelerators operating within the range of 300 keV to 1 million volts were implemented for tasks such as plastic film and tubing crosslinking, food pasteurization, and sterilization of pharmaceuticals. After HVEC ceased manufacturing accelerators in the 1970s, ICT technology was adopted by firms including Vivirad-High Voltage, Nissin-High Voltage, Sealed Air’s Cryovac division, and Wasik Associates. These ICT units continued to support wire and cable jacketing as well as shrink film applications at energy levels spanning from 300 keV up to 2.5 MeV.
Subsidiaries
In response to declining profits in 1965, HVEC restructured its operations into profit centers and established three wholly owned subsidiaries to expand beyond its particle accelerator business. With the halt of U.S. accelerator orders in the early 1970s, HVEC transformed into a miniconglomerate comprising over ten subsidiaries, whose industrial product lines accounted for approximately 80% of total revenue by 1972.
High Voltage Engineering Europa
HVEC launched High Voltage Engineering Europa (HVEE) in 1958 in Amersfoort, Netherlands to serve both the European common market and regions subject to export controls. HVEE produced HVEC’s lower-voltage Van de Graaff accelerators along with insulated-core transformer power supplies designed for low-voltage electron beam applications.
Production data up to 2004 indicates that HVEE manufactured 93 accelerators primarily within the 0.5–2 MV voltage range, along with several higher-voltage units between 4 and 7 MV. Following the bankruptcy of its parent company, HVEE continued producing solid-state voltage generators operating between 1 and 5 MV under the brand names Tandetron and Singletron—technologies originally developed by General Ionix Corporation. Moving away from belt-driven designs, HVEE’s contemporary accelerators incorporated modernized charging mechanisms.
Applied Radiation Corporation
In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO), based in Walnut Creek, California, through a stock exchange transaction. ARCO specialized in linear accelerators that complemented HVEC’s Van de Graaff models. Although ARCO remained a separate subsidiary managed by its existing leadership, its sales operations were integrated into HVEC’s organizational structure.
This acquisition was short-lived due to antitrust issues. Holding an 80% share of the research accelerator market, HVEC faced scrutiny from the Federal Trade Commission, which mandated in April 1963 that HVEC divest ARCO. This action addressed FTC concerns about excessive market concentration as both companies competed for research and industrial accelerator customers.
Electronized Chemicals Corporation
In 1943, Arno Brasch and Wolfgang Huber constructed a particle accelerator in Brooklyn aimed at irradiating and sterilizing food products without altering their flavor. They established Electronized Chemicals Corporation (ECC) to pioneer cold sterilization technologies. HVEC acquired ECC in 1957, subsequently broadening the range of radiation processing applications.
Operating near HVEC’s Burlington facility, ECC utilized HVEC's electron beam technology to offer irradiation services across various sectors and advanced polymer irradiation along with crosslinking methods. Inspired by Raychem’s innovations in low-voltage radiation cross-linking, ECC ventured into manufacturing heat-shrink tubing. In 1985, 3M purchased the business and continues to produce heat-shrink tubing at its Chelmsford, Massachusetts plant.
Ion Physics Corporation
Ion Physics Corporation originated as Goodrich-High Voltage Astronautics, Inc., a 1959 partnership between HVEC and B.F. Goodrich Company focused on developing and producing ion propulsion systems for spacecraft. Under the leadership of HVEC engineer John Gale, the firm delivered an experimental ion engine to the government’s Jet Propulsion Laboratory for evaluation.
In 1962, HVEC took full control of the company, renaming it Ion Physics Corporation. Under Gale’s direction, IPC expanded into ion bombardment methods utilized in manufacturing silicon solar cells and semiconductor devices. Employing Van de Graaff accelerators to implant ions into silicon wafers, IPC made significant progress by the mid-1960s, including:
- Achieving a new efficiency milestone for silicon solar cell technology
- Fabricating the first bipolar junction transistor using ion-implanted p-n junctions
- Creating annealing techniques to restore crystal structure damaged by ion implantation
In 1969, Fairchild Semiconductor engaged HVEC to design a low-energy ion accelerator tailored for semiconductor fabrication. This project confirmed that ion implantation could accurately position dopants within silicon wafers, establishing it as a practical method for the nascent integrated circuit industry. Peter H. Rose, HVEC's research director, quickly assembled a working prototype from spare components. Ion implantation provided manufacturers with superior control over transistor electrical characteristics compared to conventional diffusion processes.
Following the resignation of three senior executives in December 1969, Rose assumed the presidency of IPC. Despite his efforts, IPC was unable to commercialize ion implantation equipment successfully. In 1971, Rose departed to establish Extrion Corporation with support from Denis Robinson, leading to HVEC’s closure of IPC. Extrion later became a dominant force in ion implanter production, and by the late 1970s, ion implantation had become integral to integrated circuit manufacturing.
High Voltage Power Corporation
In July 1968, High Voltage Engineering Corporation partnered with Reynolds Metals Company to create High Voltage Power Corporation, a joint venture dedicated to developing and marketing gas-insulated systems for underground electric power transmission. HVEC president Denis Robinson emphasized increasing demand for buried transmission lines driven by technological advancements, economic considerations, and aesthetic preferences. He noted that compressed gas offered reliable high-voltage power transmission at reduced costs. Both companies held equal ownership stakes; Reynolds contributed capital and research capabilities while HVEC provided patents and technical expertise. The venture’s development activities took place at HVEC’s Burlington site.
The subsidiary manufactured insulating-core reactors for nuclear power plants and gas-insulated transmission systems derived from Van de Graaff’s insulating-core transformer innovation. However, by 1974 the venture was incurring losses that accounted for 60-75% of HVEC’s cash flow despite generating only $1.5-2 million in annual revenue, leading HVEC to exit the business.
Venture capital and commercial spin-offs
HVEC illustrated fundamental aspects of American venture capital investment strategies. The company’s 1955 initial public offering yielded a ninefold return on ARD’s original capital, ensuring the fund’s continuation and facilitating its 1957 backing of Digital Equipment Corporation. According to historian Paul Gompers, DEC’s $355 million payoff set the precedent for the "home run" approach, where one outstanding success validates a portfolio composed of numerous high-risk ventures. HVEC reflected ARD’s methodology of hands-on management, careful selection of scientific expertise, and concentration on technology-driven industries characterized by substantial barriers that support enduring profitability.
Scientific impact
HVEC represented a pivotal transition from laboratory-constructed to commercially produced large-scale scientific apparatus. Historian John McKay recognized HVEC's CN series (1951–1966) as the inaugural line of mass-manufactured research accelerators. Science advisor D. Allan Bromley commended the tandem series as "exceptional instruments for nuclear science," instrumental in achieving groundbreaking nuclear research milestones. By 1984, Bromley regarded large tandem accelerators as covering the widest range and scope within nuclear physics.
HVEC was a trailblazer in accelerator mass spectrometry (AMS), significantly enhancing radiocarbon dating techniques. In 1977, researchers at the University of Rochester utilized an HVEC MP tandem to directly detect carbon-14 in milligram quantities—dramatically less than the 10 to 100 grams required by traditional methods. This advancement allowed for precise dating of valuable artifacts and archaeological samples without destruction, achieving an accuracy close to ±80 years. Tandem accelerators extended radiocarbon dating’s effective limit from approximately 40,000 years to potentially 100,000 years by removing nitrogen-14 interference through their distinctive ion acceleration process. Beyond radiocarbon applications, tandem accelerators facilitated measurement of rare isotopes across hydrology, geosciences, biomedicine, archaeology, and paleoclimatology.
Radiation technology applications
A worldwide survey conducted in 2010 revealed that among the 26,000 low-energy particle accelerators globally, the principal commercial uses were radiotherapy (44%), ion implantation (41%), and industrial processing and research (9%). HVEC made significant contributions across all these domains.
Radiation physicist Milford Schulz highlighted HVEC's Van de Graaff cancer generators as providing hospitals with cost-effective high-voltage artificial radiation sources, marking important advances in radiotherapy technology. The first medical linear accelerator—now the standard device in radiotherapy—was constructed by Ed Ginzton at Stanford University utilizing an HVEC unit.
HVEC accelerators also led the way in commercial radiation sterilization of medical supplies. Ion Physics Corporation, a subsidiary of HVEC, demonstrated ion implantation’s precision in modifying transistor properties for integrated circuits. Following financial setbacks in the early 1970s, former HVEC personnel established companies manufacturing production-level ion implanters. By decade’s end, ion implantation had become indispensable in semiconductor fabrication, enabling MOS integrated circuits that dominated late 20th-century electronics markets.
Ongoing scientific applications
Even though HVEC ceased producing research accelerators in 1973, at least 32 units remain operational within nuclear physics laboratories as of 2025. Their extended service life highlights both durable construction and sustained importance in scientific investigations, with certain devices functioning for more than five decades through systematic modernization.
These accelerators facilitate a wide array of studies, such as accelerator mass spectrometry (AMS) employed in radiocarbon dating, nuclear astrophysics focused on neutron-induced processes and nuclear cross-section measurements relevant to stellar nucleosynthesis, materials analysis, radiation damage experiments, and investigations into ion-atom collision phenomena.
High Voltage Engineering Europa, formerly HVEC’s Dutch branch, continues to produce lower-voltage electrostatic accelerators designed for both research and industrial applications.
Notes: Bromley (1974) lists original installation years; several accelerators have been relocated after their initial setup.
External links
- Comprehensive list of active research accelerators provided by the International Atomic Energy Agency
- High Voltage Engineering Corporation Bulletin PA (1958), available via Duke University